Sunway Healthcare Holdings Berhad IPO's Analysis

Sunway Healthcare Holdings Berhad

Sunway Healthcare Holdings Berhad (SHH) is one of Malaysia's largest private hospital groups, providing a full lifecycle of care. Its flagship, Sunway Medical Centre Sunway City Kuala Lumpur, is a quaternary hospital and one of the largest in Southeast Asia. The network also includes four tertiary hospitals in key urban areas. Beyond hospital operations, SHH operates ancillary healthcare businesses, including ambulatory care centres (Sunway Specialist Centre and Sunway Fertility Centre), and supportive care facilities like Sunway TCM Centres, Sunway Home Healthcare, and the Sunway Sanctuary integrated senior living facility. The company is focused on expanding its footprint in Malaysia through both brownfield expansions of existing hospitals and greenfield development of new tertiary hospitals in underserved regions.

IPO Details
Market: Main
Principal Adviser: Maybank Investment Bank Berhad and AmInvestment Bank Berhad
Shariah Status: SC (Yes)
Listing Price: 1.45
PE Ratio: 64.8-89.4
    PE (FYE): 64.8
    PE (FPE Annualised): 89.44
    PE (Hybrid): 76.41
MITI allocation?: Yes
Closing Date: 05-Mar-2026
Balloting Date: 10-Mar-2026
Listing Date: 18-Mar-2026
Average Analysts FV :
TA (1.62), Public Invest (1.45), Mplus (1.51), Tradeview (1.51)
iSaham IPO Score :
Market Cap: 16,675.25 M
Number of Shares: 11,500.17 M
IPO Allocations No. of Shares %
Malaysian Public 230.00 M 2.0%
Bumiputera shareholders approved by MITI 747.51 M 6.5%
Eligible Directors and employees 115.0 M 1.0%
Private placement to selected investors and others 876.48 M 7.62%
Total Allocations 1,968.99 M 17.12%

Offer for Sales of 1,393.99 M existing shares representing 12.12% enlarged shares.

Public Issue of 575.01 M new shares representing 5.0% enlarged shares.

Median Sectors PE:
Median Peers PE:
Strategic Overview & Data Visuals
Pro Insight Image 0
Pro Insight Image 1
Pro Insight Image 2
Pro Insight Image 3
Pro Insight Image 4
Pro Insight Image 5
Pro Insight Image 6
Pro Insight Image 7
Pro Insight Image 8
Pro Insight Image 9
Pro Insight Image 10
Pro Insight Image 11
Pro Insight Image 12
Pro Insight Image 13
Pro Insight Image 14
Pro Insight Image 15
Pro Insight Image 16
Pro Insight Image 17
Pro Insight Image 18
Pro Insight Image 19
Pro Insight Image 20
Pro Insight Image 21
Pro Insight Image 22
Pro Insight Image 23
Pro Insight Image 24
Pro Insight Image 25
Pro Insight Image 26
Pro Insight Image 27
Pro Insight Image 28
Pro Insight Image 29
Pro Insight Image 30
Pro Insight Image 31
Pro Insight Image 32
Pro Insight Image 33
Pro Insight Image 34
Pro Insight Image 35
Pro Insight Image 36
Pro Insight Image 0
Pro Insight Image 1
Pro Insight Image 2
Pro Insight Image 3
Pro Insight Image 4
Pro Insight Image 5
Pro Insight Image 6
Pro Insight Image 7
Pro Insight Image 8
Pro Insight Image 9
Pro Insight Image 10
Pro Insight Image 11
Pro Insight Image 12
Pro Insight Image 13
Pro Insight Image 14
Pro Insight Image 15
Pro Insight Image 16
Pro Insight Image 17
Pro Insight Image 18
Pro Insight Image 19
Pro Insight Image 20
Pro Insight Image 21
Pro Insight Image 22
Pro Insight Image 23
Pro Insight Image 24
Pro Insight Image 25
Pro Insight Image 26
Pro Insight Image 27
Pro Insight Image 28
Pro Insight Image 29
Pro Insight Image 30
Pro Insight Image 31
Pro Insight Image 32
Pro Insight Image 33
Pro Insight Image 34
Pro Insight Image 35
Pro Insight Image 36
Utilisation of Proceeds
Purpose Amount (RM'000) %
Expansion Capital expenditure for expansion of our existing hospitals 554,050 66.5
Listing expenses Defray fees and expenses in relation to our IPO and Listing 30,000 3.6
Debt Redemption of the Sukuk Wakalah 249,712 29.9
Total 833,762 100
Analyst Highlights
Date Analyst Highlights
05-Mar-2026 
TradeView
  • Index Inclusion as a Key Valuation Catalyst: Benchmarking SHH against IHH Healthcare's post-IPO valuation, expecting FBM KLCI index inclusion to drive passive inflows and stronger growth trajectory.
  • International Patient Growth and Expansion Drive Visibility: Well-positioned to benefit from Malaysia's medical tourism, with foreign patient revenue growing significantly and supported by a clear expansion pipeline.
  • Premium Positioning Margin Strength: Focus on tertiary and quaternary care strengthens premium brand, supporting higher revenue intensity per patient, strong brand equity leading to pricing power and stable GP margins.
05-Mar-2026 
Mplus
  • Projected 12.6% 3-year earnings CAGR with core PATMI reaching RM368.1m, supported by brownfield expansions, medical tourism, and aging population.
  • Fair value of RM1.51 (4.1% upside from IPO price RM1.45) based on 25.5x EV/EBITDA, reflecting strong growth prospects and valuation.
  • Replicable business model with fast earnings ramp-up, achieving positive EBITDA for new centres faster than the industry average.
  • Aggressive network expansion plans to increase total bed capacity from 1,520 (2024) to over 3,400 by 2032 through various expansions.
04-Mar-2026 
TA
  • Replicable Business Model with Clear Growth Potentials, evidenced by strong operational expertise and rapid ramp-up of greenfield projects.
  • Growing Medical Tourism, with robust recognition among international patients, contributing significantly to medical tourism revenue and higher bill sizes.
04-Mar-2026 
Public Invest
  • Market leadership and better penetration: Sunway Healthcare aims to strengthen its market leadership by expanding capacity of its existing hospital network and via greenfield investments to capture rising demand.
  • Leadership in clinical excellence: The Group intends to maintain its leadership position by continuously strengthening clinical excellence and expanding its range of tertiary and quaternary care services.
Utilisation of Proceeds
Business Segments
Geographical Segments
Revenue by Financial Year Ended
Profit After Tax (PAT) by Financial Year Ended
Revenue by Financial Period Ended
Profit After Tax (PAT) by Financial Period Ended
SWOT Analysis
Strengths
  • Integrated Township Ecosystem: Hospitals are embedded within Sunway's townships, creating a captive market and synergies for medical tourism with co-located hotels and retail, a unique advantage over standalone competitors.
  • High Revenue Intensity: Focus on high-complexity Quaternary and Tertiary care results in higher revenue per patient and stronger margins compared to general hospital peers.
  • Strong Institutional Backing: Backed by GIC, Singapore’s Sovereign Wealth Fund, which validates the company's quality and provides financial credibility for future growth and potential regional expansion.
Weaknesses
  • Extreme Valuation Premium: Listing at a Hybrid PE ratio of 76.41x, a premium of over 100% compared to established peers like IHH Healthcare (~34.5x) and KPJ Healthcare (~35.5x), leaving little room for error.
  • Flagship Hospital Dependency: The Sunway City Kuala Lumpur hospital contributes approximately 64.8% of group revenue, posing a significant concentration risk to earnings if its operations are disrupted.
  • Short-Term Earnings Drag: Aggressive expansion and gestation costs from new hospitals have caused a 21.9% drop in recent profits, suppressing short-term returns and making the high valuation appear even more stretched.
Opportunities
  • Medical Tourism Growth: Positioned to capture the recovery in medical tourism, leveraging Malaysia's cost-competitiveness and quality of care to attract patients from Indonesia and Singapore.
  • Ageing Demographics: Malaysia's shift towards an aged nation status will drive intrinsic demand for specialised healthcare services like geriatric care and chronic disease management, which SHH is equipped to provide.
  • Cross-Border Market Tapping: The upcoming hospital in Iskandar Puteri, Johor, provides a strategic entry point to tap into the Singaporean patient market, capitalizing on significant cost arbitrage.
Threats
  • Healthcare Talent Shortage: An acute shortage of nurses and specialist doctors in Malaysia could drive up staff costs and constrain the operational capacity and ramp-up speed of new hospitals.
  • Increased Competition: Regulatory changes effective September 2024 lower the barriers to entry for new private hospitals, which could intensify competition from new market players in the long term.
  • Insurance and Cost Pressures: Rising medical inflation may lead insurance providers to tighten claim policies or increase premiums, potentially impacting patient volumes and revenue streams.
Key Highlights

Sorry, this feature only available for iSaham Pro

Conclusion

Sorry, this feature only available for iSaham Pro

Sunway Healthcare Holdings Berhad's Latest News